| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:40 UTC |
|---|
| HMDB ID | HMDB0014600 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Prazosin |
|---|
| Description | Prazosin is a selective α-1-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma. |
|---|
| Structure | COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1 InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22) |
|---|
| Synonyms | | Value | Source |
|---|
| 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine | ChEBI | | 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline | ChEBI | | Prazosina | ChEBI | | Prazosine | ChEBI | | Prazosinum | ChEBI | | Minipress | Kegg | | Prazocin | HMDB | | Furazosin | HMDB | | Hydrochloride, prazosin | HMDB | | Pfizer brand OF prazosin hydrochloride | HMDB | | Douglas brand OF prazosin hydrochloride | HMDB | | Prazosin HCL | HMDB | | HCL, Prazosin | HMDB | | Pratsiol | HMDB | | Prazosin hydrochloride | HMDB |
|
|---|
| Chemical Formula | C19H21N5O4 |
|---|
| Average Molecular Weight | 383.4011 |
|---|
| Monoisotopic Molecular Weight | 383.159354185 |
|---|
| IUPAC Name | 2-[4-(furan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine |
|---|
| Traditional Name | prazosin |
|---|
| CAS Registry Number | 19216-56-9 |
|---|
| SMILES | COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1 |
|---|
| InChI Identifier | InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22) |
|---|
| InChI Key | IENZQIKPVFGBNW-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazinanes |
|---|
| Sub Class | Piperazines |
|---|
| Direct Parent | N-arylpiperazines |
|---|
| Alternative Parents | |
|---|
| Substituents | - N-arylpiperazine
- Quinazolinamine
- Diazanaphthalene
- Quinazoline
- 2-heteroaryl carboxamide
- Furoic acid or derivatives
- Anisole
- Dialkylarylamine
- Alkyl aryl ether
- Aminopyrimidine
- Benzenoid
- Pyrimidine
- Imidolactam
- Tertiary carboxylic acid amide
- Heteroaromatic compound
- Furan
- Carboxamide group
- Amino acid or derivatives
- Carboxylic acid derivative
- Ether
- Oxacycle
- Azacycle
- Organic oxygen compound
- Amine
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organonitrogen compound
- Organooxygen compound
- Primary amine
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 279 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.69 g/L | Not Available | | LogP | 1.3 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 192.7 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.92 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.3322 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.37 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 51.4 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 834.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 203.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 134.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 173.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 73.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 288.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 418.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 526.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 699.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 292.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1280.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 266.4 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 289.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 417.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 293.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 34.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Prazosin,1TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N[Si](C)(C)C)=C2C=C1OC | 3744.7 | Semi standard non polar | 33892256 | | Prazosin,1TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N[Si](C)(C)C)=C2C=C1OC | 3249.2 | Standard non polar | 33892256 | | Prazosin,1TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N[Si](C)(C)C)=C2C=C1OC | 5301.9 | Standard polar | 33892256 | | Prazosin,2TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 3648.7 | Semi standard non polar | 33892256 | | Prazosin,2TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 3198.7 | Standard non polar | 33892256 | | Prazosin,2TMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC | 4866.5 | Standard polar | 33892256 | | Prazosin,1TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3913.4 | Semi standard non polar | 33892256 | | Prazosin,1TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3416.9 | Standard non polar | 33892256 | | Prazosin,1TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC | 5207.1 | Standard polar | 33892256 | | Prazosin,2TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3997.7 | Semi standard non polar | 33892256 | | Prazosin,2TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 3623.3 | Standard non polar | 33892256 | | Prazosin,2TBDMS,isomer #1 | COC1=CC2=NC(N3CCN(C(=O)C4=CC=CO4)CC3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC | 4763.0 | Standard polar | 33892256 |
|
|---|
| General References | - Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I: Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):49-56. Epub 2003 Jun 25. [PubMed:12827214 ]
- Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]
- Bawaskar HS, Bawaskar PH: Utility of scorpion antivenin vs prazosin in the management of severe Mesobuthus tamulus (Indian red scorpion) envenoming at rural setting. J Assoc Physicians India. 2007 Jan;55:14-21. [PubMed:17444339 ]
- Sigma Aldrich [Link]
|
|---|